We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 or complete the questionnaire at this link to be contacted about future studies.
Comparing Fingerstick Blood Glucose Monitoring versus Continuous Glucose Monitoring in Primary Care (The “GluCoCare” Study: GLUcose monitoring COmparison in primary CARE)
Principal Investigator: Richard Bergenstal, MD, Thomas Martens, MD
Study sponsor: Patient-Centered Outcomes Research Institute
Location: 10 select Primary Care Clinics across the HealthPartners network
Purpose of study: Your primary care clinic providers are partnering with the International Diabetes Center to invite you to join the GluCoCare study, a study looking at how using fingerstick blood glucose monitoring (BGM) compares to using continuous glucose monitoring (CGM) to manage type 2 diabetes in people using insulin.
In case you’re not familiar with a CGM, it is a device used to measure your glucose level every few minutes, 24 hours a day. CGM lets you see your current glucose level and shows you if your glucose is going up, down or staying steady. You can also see daily glucose patterns over time.
While it is known that controlling blood glucose is important in managing diabetes, especially when using insulin, it is not yet known which of the two ways to measure blood glucose is better. This important study will help people with type 2 diabetes know which method of measuring glucose is more helpful in improving glucose levels and decreasing the work of managing diabetes. We’re hoping you’ll partner with us to learn if using BGM or CGM is better to help manage blood glucose.
Inclusion Criteria:
This study is accepting individuals ages 18-75 who:
– Have type 2 diabetes
– Have a hemoglobin A1c 7.5-12
– Currently use insulin
– Are not currently using continuous glucose monitoring
– Currently receiving care at one of 30 clinics within the HealthPartners system
– Meet other study specific requirements
Participants will receive compensation for completed study visits up to a total of $250 if all visits are completed.
If you are interested in participating and would like to see if you are eligible, please click here to answer some eligibility questions.
Study Contact:
GluCoCare Team
(952) 967-5805
Dexcom Continuous Glucose Monitoring System Use in a Real-World, Global Registry (Dexcom Global Registry)
Principal Investigator: Thomas Martens, MD
Study sponsor: Dexcom, Inc.
Location: International Diabetes Center
Purpose of study: The purpose of this research study is to evaluate the use of the Dexcom CGM System and to study the device’s impact on individuals in their daily life. The CGM is a small device worn on the body that allows you to see what your glucose is at any time of the day. The system has a sensor that measures a person’s glucose level continuously and the glucose numbers can be seen on your smartphone or a receiver for the CGM. People can use information from a CGM to help make choices about food, activity, and medication in a way that works for their diabetes.
Participants will receive:
Payment for completed questionnaires, up to $10 for each questionnaire, and $50 for completion of the initial study visit for a total of up to $590 if all questionnaires are completed over 12 months of participation.
Inclusion Criteria:
You may qualify if you:
– Have type 2 diabetes
– Do NOT take insulin
– Have never used a CGM, or have not used one recently
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
[email protected]
Dexcom Continuous Glucose Monitoring System Use in a Real-World, Global Registry (Dexcom Global Registry)
Principal Investigator: Thomas Martens, MD
Study sponsor: Dexcom, Inc.
Location: International Diabetes Center
Purpose of study: The purpose of this research study is to evaluate the use of the Dexcom CGM System and to study the device’s impact on individuals in their daily life. The CGM is a small device worn on the body that allows you to see what your glucose is at any time of the day. The system has a sensor that measures a person’s glucose level continuously and the glucose numbers can be seen on your smartphone or a receiver for the CGM. People can use information from a CGM to help make choices about food, activity, and medication in a way that works for their diabetes.
Participants will receive payment for completed questionnaires, up to $10 for each questionnaire, and $50 for completion of the initial study visit for a total of up to $590 if all questionnaires are completed over 12 months of participation.
Inclusion Criteria:
You may qualify if you:
– Have type 2 diabetes
– Do NOT take insulin
– Have never used a CGM, or have not used one recently
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
[email protected]
IMPACT2: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2 – Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Medtronic
Location: International Diabetes Center
Purpose of study: The purpose of this study is to see how well the Minimed 780G insulin pump system works to automatically infuse insulin for control of glucose levels for people with type 2 diabetes who use insulin. This Medtronic MiniMed 780G system consists of an insulin pump, a glucose sensor, a transmitter, and a glucose meter. The system uses continuous glucose readings from the sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 2 diabetes. The MiniMed 780 System and related supplies are provided for use during the study at no cost to qualifying participants.
Involvement in the trial will include:
• Compensation for completed study visits
• Diabetes management and education, support and guidance by diabetes professionals
• Study-related medical care, including regular health checks and lab tests provided at no cost to you
Inclusion Criteria:
The study is accepting individuals ages 18-80 who:
– Have had type 2 diabetes for 2 years or longer
– Take insulin injections or use an insulin pump
– Are willing to use Humalog or Novolog insulin throughout the study
– Meet other study specific criteria
Study Contact:
Caitlin Moening
(952) 993-9605
[email protected]
MyDiabetes Study
Principal Investigator: Holly Willis, PhD, RDN, CDCES
Study sponsor: American Diabetes Association, Dexcom, Park Nicollet Foundation
Location: International Diabetes Center
Purpose of study: This study will test whether there is a difference between two different ways of helping someone learn how to use a continuous glucose monitor (CGM) and how that affects a person’s glucose. The CGM is a small device worn on your abdomen that allows you to see what your glucose is at any time of the day. People can use information from a CGM to help make choices about food, activity, and medication in a way that works for their diabetes.
All participants in the study will be provided with the Dexcom G6 CGM system. The system has a sensor that measures a person’s glucose level continuously and the glucose numbers can be seen on the person’s smartphone.
Participants will receive the following, at no cost:
• Study-related medical care including diabetes education and lab tests
• Dexcom G6 CGM systems for use during the study
• Payment for completed visits
To learn more, visit our site: https://redcap.link/qyd133pv.
For questions, email [email protected]
or call 952-993-9605 and refer to the “MyDiabetes CGM study.”
Inclusion Criteria:
– Are age 18 or older
– Have type 2 diabetes
– Do NOT take insulin
– Have an A1C between 7.0%-10.0%
– Have never used a CGM, or have not used on recently
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
[email protected]
Open, Single Arm, Prospective, Multicenter Study of an Investigational Extended Wear Insulin Infusion Set During Home Use in People with Type 1 Diabetes (SteadiSet Study)
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Capillary Biomedical
Location: International Diabetes Center
Purpose of study: This study will see how well a new investigational insulin infusion set works for people with type 1 diabetes using the Tandem Control-IQ pump. This infusion set is designed to last for at least 7 days without needing to be changed. This study is being done to find out whether the infusion set can be used safely for up to 7 days before replacement.
Involvement in the trial will include:
– Pump and infusion set supplies used during the study, provided at no cost
– Diabetes management and education, support and guidance by diabetes
professionals
– Participation in the study for about 12 weeks
– Payment for completed visits and completing study requirements
Inclusion Criteria:
The study is accepting males and females 18-80 years old and:
– Have type 1 diabetes and use a Tandem t:slim X2 insulin pump with Control-IQ
– Have a hemoglobin A1c less than 9.0%
– Are willing to use the study infusion sets throughout the study as directed by the
research team.
– Are willing and able to upload device data weekly
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
[email protected]
Piqray CGM IIT: Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib (CBYL719A0US16T)
Principal Investigator: Dylan Zylla, MD, Richard Bergenstal, MD
Study sponsor: HealthPartners Institute
Location: HealthPartners Cancer Center at Regions Hospital, HealthPartners Frauenshuh Cancer Center
Phase of Study: II
Purpose of study: The purpose of the study is to characterize and understand the impact of alpelisib on glucose control in patients with breast cancer using Continuous Glucose Monitoring (CGM) and following a hyperglycemia prevention and management regimen.
Inclusion Criteria:
– Adults age 18+ with diagnosis of metastatic Breast cancer that are initiating treatment with Alpelisib.
– Must be willing to and comply with study visits and procedures.
– Must meet standard clinical criteria for utilizing Alpelisib, including Hormone-receptor positive/HER2 negative cancer with presence of PIK3CA mutation.
– Treating oncologist must plan to use Alpelisib until disease progression or unacceptable toxicity.
– Patient must receive cancer care with a HealthPartners Oncologist during Alpelisib treatment phase and must be willing to see IDC/HealthPartners Diabetes Education for diabetes management.
– Must have compatible smartphone, access to compatible smartphone, or ability to digitally upload information from Continuous Glucose Monitor (CGM), or to bring the reader in to the medical visit at least once a month for uploading data.
– Must have life expectancy of at least 3 months.
Exclusion Criteria:
– Has known history or allergy to skin-adhesive material, or previous cutaneous reaction to a continuous glucose monitor.
– Known currently uncontrolled diabetes, defined as most recent HbA1c over 10%, or history of DKA within 6 months prior to enrollment.
– Concurrent use of high-dose vitamin C, defined as more than 1g of oral vitamin C daily, or IV vitamin C infusions.
– Any concurrent severe, or uncontrolled condition that, in the opinion of the investigator, would cause safety risk, compromise protocol compliance, or contraindicate patient’s participation in the study.
Study Contact:
Alissa Gavenda, RN
(952) 992-5705
[email protected]
REIMAGINE 4: A research study to see how much CagriSema lowers blood sugar and body weight compared to tirzepatide in people with type 2 diabetes treated with metformin with or without an SGLT2 inhibitor
Principal Investigator: Thomas Martens, MD
Study sponsor: Novo Nordisk
Phase of study: III
Location: International Diabetes Center
Purpose of study: We will provide people with type 2 diabetes one of two different medications at no cost, to see how much it helps with managing blood sugars and weight loss. We are doing this study to look at how much the new investigational medicine called CagriSema improves blood sugar and lowers body weight in people with type 2 diabetes. This will be compared to a currently available medicine called tirzepatide (Mounjaro).
CagriSema is a combination of cagrilintide and semaglutide (Ozempic). Both can lower blood sugar and body weight, and they appear to do so more when combined than alone. Doctors can prescribe semaglutide to treat people with type 2 diabetes. Cagrilintide is a new investigational medicine under development. Tirzepatide is a medicine that can lower blood sugar and body weight. This medication is available for doctors to prescribe to help with type 2 diabetes and weight management. Participants in the study will be randomly assigned to take one of these two medications once a week, while continuing to take their usual diabetes medications.
Participants will receive:
– Study medication provided at no cost
– Glucose meter and supplies used during the study, provided at no cost
– Compensation for time and travel for completed study visits
– Subject may receive stipend of up to $75 for each clinic visit and up to $25 for each remote visit
– Guidance by diabetes and nutrition professionals
– Study-related medical care, including regular lab tests, eye exams and EKGs provided at no cost
Inclusion Criteria:
The study is accepting individuals ages 18 and older who:
– Have type 2 diabetes
– Are taking metformin, either alone or with another medicine for diabetes
– Have an A1C 7-10.5%.
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
[email protected]
REIMAGINE 4: A research study to see how much CagriSema lowers blood sugar and body weight compared to tirzepatide in people with type 2 diabetes treated with metformin with or without an SGLT2 inhibitor
Principal Investigator: Thomas Martens, MD
Study sponsor: Novo Nordisk
Location: International Diabetes Center
Phase of Study: III
Purpose of study: We will provide people with type 2 diabetes one of two different medications at no cost, to see how much it helps with managing blood sugars and weight loss. We are doing this study to look at how much the new investigational medicine called CagriSema improves blood sugar and lowers body weight in people with type 2 diabetes. This will be compared to a currently available medicine called tirzepatide (Mounjaro).
CagriSema is a combination of cagrilintide and semaglutide (Ozempic). Both can lower blood sugar and body weight, and they appear to do so more when combined than alone. Doctors can prescribe semaglutide to treat people with type 2 diabetes. Cagrilintide is a new investigational medicine under development. Tirzepatide is a medicine that can lower blood sugar and body weight. This medication is available for doctors to prescribe to help with type 2 diabetes and weight management. Participants in the study will be randomly assigned to take one of these two medications once a week, while continuing to take their usual diabetes medications.
Participants will receive:
– Study medication provided at no cost
– Glucose meter and supplies used during the study, provided at no cost
– Compensation for time and travel for completed study visits
– Subject may receive stipend of up to $75 for each clinic visit and up to $25 for each remote visit completed
– Guidance by diabetes and nutrition professionals
– Study-related medical care, including regular lab tests, eye exams and EKGs provided at no cost
Inclusion Criteria:
The study is accepting individuals ages 18 and older who:
– Have type 2 diabetes
– Are taking metformin, either alone or with another medicine for diabetes
– Have an A1C 7-10.5%.
– Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
[email protected]
Weight Loss Wizard: Patient Perspective Interviews (Weight Loss Wizard)
Principal Investigator: Patrick O’Connor, MD, MPH, MA
Study sponsor: NIH/NIDDK
Location: Enrolled participants do not need to travel
Purpose of study: The Weight Loss Wizard participant interview is supported by National Institutes of Health to gather input from patients about their experiences with talking to their primary care doctors about weight loss options. The information gathered will help guide design and content of a shared decision-making tool used at the point of care. The interview is being offered via phone or conference call to patients with Type 2 Diabetes.
Inclusion Criteria:
-Patients with Type 2 Diabetes
Exclusion Criteria:
-Previous metabolic bariatric surgery
Study Contact:
Center for Evaluation and Survey Research
(952) 967-6912
[email protected]